Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

    Virtual Booth

    Contact Supplier

    Chirogate is a professional Prostaglandin manufacturer.

    Virtual Booth

    Contact Supplier

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Skyepharma, an Expert and Innovative CDMO Partner for tailor-made solutions in complex oral solids and bioproduction.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Menu

    Bezuclastinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Cogent’s Bezuclastinib Hits All Endpoints in SUMMIT Trial
    Cogent’s Bezuclastinib Hits All Endpoints in SUMMIT Trial

    08 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/07/3110920/0/en/Cogent-Biosciences-Announces-Positive-Top-line-Results-Achieving-Statistical-Significance-Across-All-Primary-and-Key-Secondary-Endpoints-from-the-SUMMIT-Trial-of-Bezuclastinib-in-P.html

    GLOBENEWSWIRE
    08 Jul 2025
    Share Share
    Cogent Hits Primary Endpoint, Building Case for Blueprint Rival
    Cogent Hits Primary Endpoint, Building Case for Blueprint Rival

    07 Jul 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/cogents-phase-3-hits-primary-endpoint-building-case-filing-challenge-blueprints-ayvakit

    FIERCE BIOTECH
    07 Jul 2025
    Share Share
    Cogent Previews 2025 Goals For Bezuclastinib & Targeted Drugs
    Cogent Previews 2025 Goals For Bezuclastinib & Targeted Drugs

    13 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/13/3008475/0/en/Cogent-Biosciences-Announces-Planned-2025-Milestones-for-Bezuclastinib-and-Emerging-Portfolio-of-Selective-and-Potent-Targeted-Therapeutics.html

    GLOBENEWSWIRE
    13 Jan 2025
    Share Share
    Cogent Biosciences Presents Bezuclastinib Data at ASH 2024
    Cogent Biosciences Presents Bezuclastinib Data at ASH 2024

    05 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/05/2974974/0/en/Cogent-Biosciences-Announces-Bezuclastinib-Presentations-at-the-66th-Annual-American-Society-of-Hematology-ASH-Meeting.html

    GLOBENEWSWIRE
    05 Nov 2024
    Share Share
    Cogent Reports Additional Bezuclastinib Data In NonAdvSM
    Cogent Reports Additional Bezuclastinib Data In NonAdvSM

    14 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/14/2898928/0/en/Cogent-Biosciences-Announces-Additional-Clinical-Data-from-Part-1-of-its-Ongoing-SUMMIT-Trial-Evaluating-Bezuclastinib-in-Patients-with-NonAdvanced-Systemic-Mastocytosis-NonAdvSM.html

    GLOBENEWSWIRE
    14 Jun 2024
    Share Share
    Cogent Bezuclastinib Peak Lead-In: Gist Phase 3 Positive At Asco
    Cogent Bezuclastinib Peak Lead-In: Gist Phase 3 Positive At Asco

    23 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/23/2887694/0/en/Cogent-Biosciences-Announces-Positive-Updated-Lead-In-Data-from-Ongoing-Phase-3-PEAK-Trial-Evaluating-Bezuclastinib-in-Combination-with-Sunitinib-in-Patients-with-Gastrointestinal-.html

    GLOBENEWSWIRE
    23 May 2024
    Share Share